These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15485306)

  • 21. Lymphoma researchers in search of molecular targets.
    Friedrich MJ
    J Natl Cancer Inst; 2010 Jul; 102(14):1000-1. PubMed ID: 20616351
    [No Abstract]   [Full Text] [Related]  

  • 22. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 23. Accelerated approval of oncology products: a decade of experience.
    Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
    J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer drugs. Weighing the risks and benefits.
    Bren L
    FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

  • 26. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 27. Lessons learnt from Genasense's failure.
    Frantz S
    Nat Rev Drug Discov; 2004 Jul; 3(7):542-3. PubMed ID: 15272494
    [No Abstract]   [Full Text] [Related]  

  • 28. Better prioritization may speed approval of adjuvant therapies in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2008 Jun; 100(12):842-4. PubMed ID: 18544735
    [No Abstract]   [Full Text] [Related]  

  • 29. [Introduction and consideration of the anti-cancer drug evaluation strategy in Europe and America].
    Tang JY; Ma L; Zhang L
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):798-800. PubMed ID: 19173820
    [No Abstract]   [Full Text] [Related]  

  • 30. How vaccines are developed.
    Douglas RG
    Curr Clin Top Infect Dis; 1994; 14():192-204. PubMed ID: 8086115
    [No Abstract]   [Full Text] [Related]  

  • 31. Endpoints for assessing drug activity in clinical trials.
    Pazdur R
    Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA starts moving on critical path, but initiative running out of steam.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
    [No Abstract]   [Full Text] [Related]  

  • 33. The Genasense 'learning curve'.
    Stein CA
    Nat Biotechnol; 2007 Sep; 25(9):972-3; author reply 973. PubMed ID: 17846618
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 35. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
    Roden DM; Temple R
    Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
    [No Abstract]   [Full Text] [Related]  

  • 36. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
    McBride D
    ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636
    [No Abstract]   [Full Text] [Related]  

  • 37. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expanded access program in the United States and Alimta program for malignant mesothelioma patients].
    Nambu Y
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):284-6. PubMed ID: 17301544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs, diagnostic tests approved quickly.
    Rose S
    Cancer Discov; 2011 Oct; 1(5):371. PubMed ID: 22586620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.